ProCE Banner Activity

Key Issues in Myeloma Treatment Today

Conference Coverage
Clinical Thought
Join me as I discuss my thoughts on key topical issues in the care of patients with myeloma, including the management of smoldering myeloma, treatment options for patients with high-risk multiple myeloma, and novel immunotherapy constructs.

Released: November 23, 2020

Expiration: November 22, 2021

No longer available for credit.

Share

Faculty

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Bristol Myers Squibb

GlaxoSmithKline

Karyopharm

Oncopeptides

Partners

International Myeloma Foundation

ProCE Banner

Faculty Disclosure

Primary Author

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has disclosed that he has received funds for research support from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, MedImmune, Oncopeptides, Takeda, and TeneoBio, and consulting fees from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Oncopeptides, and Takeda.